Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a ...

Image Source: Zacks Investment Research Opinion Based on Data from MRK’s KEYNOTE-868 & KEYNOTE-A18 Studies The positive CHMP opinion for the endometrial carcinoma indication was based on data from the ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Photo: John Moore/Getty Images Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.

The trial, which took place in China, was hotly anticipated as Keytruda has been the standard of care in this lucrative setting since its approval in 2017. Approximately 80% of patients have a PD ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

The company (MRK) said the approval is the first for Keytruda to treat MPM in the U.S. and is in combination with pemetrexed and platinum chemotherapy. MPM is a rare and aggressive malignancy ...